nirsevimab
nirsevimab is listed in the FDA National Drug Code directory with 9 NDC codes, marketed under brand name including BEYFORTUS. Available dosage forms: injection, injection, solution, liquid.
Drug Details
- Generic Name
- nirsevimab
- Brand Names
- BEYFORTUS
- Application Number
- BLA761328
- Sponsor
- Sanofi Vaccines US Inc.
- NDC Codes
- 9
- Dosage Forms
- INJECTION, INJECTION, SOLUTION, LIQUID
- Routes
- INTRAMUSCULAR
- Active Ingredients
- NIRSEVIMAB
Indications and Usage
1 INDICATIONS AND USAGE BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. BEYFORTUS is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. ( 1 ) Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. ( 1 )